CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 102 enrolled
Drug / intervention
JNJ-63623872 +2 moredrug
Likely dose
JNJ-63623872 600 milligramfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02532283
NCT02532283Phase 2Completed
CompareCT.gov

A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult and Elderly Hospitalized Patients With Influenza A Infection

Janssen Research & Development, LLC·interventional·Posted Aug 25, 2015·Updated Mar 27, 2020

In Brief

A Phase 2 clinical trial evaluating JNJ-63623872, Placebo, and 1 other intervention for Influenza A Virus. Completed, enrolled 102 participants across 68 sites in 15 countries.

Detailed Summary

The purpose of this study is to evaluate the Pharmacokinetic parameters of JNJ-63623872 in combination with oseltamivir in elderly participants (aged 65 to \<= 85 years) compared to adults (aged 18 to \<= 64 years) with influenza A infection.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza A Virus
CountriesAustralia, Belgium, Brazil, Canada, France, Germany, Hong Kong, Malaysia, Netherlands, New Zealand, Singapore, Spain, Sweden, Turkey (Türkiye), United States
Collaborators--

Timeline

Phase 2CompletedFinished
20162017201820192020202120222023202420252026
First PostedAug 25, 2015
Enrollment StartDec 11, 2015
Primary CompletionFeb 24, 2017
Study CompletionMar 15, 2017
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 10.9 years ago

Interventions

JNJ-63623872drug

Participants will be administered JNJ-63623872 600 milligram (mg) tablets orally twice daily for 7 days.

Placebodrug

Participants will be administered placebo tablets orally twice daily for 7 days.

Oseltamivirdrug

Participants will be administered oseltamivir 75 mg capsules orally twice daily for 7 days.